Data completeness
3/8 — Basic
PARACORT (prednisone) by Pfizer is corticosteroid hormone receptor agonists [moa]. Approved for prostate cancer, lymphoma, rheumatoid arthritis and 20 more indications.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PARACORT is a corticosteroid hormone receptor agonist (prednisone) indicated across 23 conditions spanning oncology, rheumatology, pulmonology, immunology, and transplantation. It works by binding to glucocorticoid receptors to suppress inflammation and immune responses. The broad indication portfolio positions this as a foundational therapy across multiple therapeutic areas.
Pre-Launch
Pre-launch status indicates emerging commercial infrastructure build; hiring likely underway for brand, field, and medical affairs roles across multiple indication teams.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Worked on PARACORT at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.